Ann: Commencement of BNC210 Phase 2 Agitation Trial, page-10

Ha! I admit that choosing a control arm would be difficult as using shareholders from a non-biotech company experiencing agitated shareholders would not be admissable by the FDA.

So maybe they could use Biotron or Phosphagenics or Actinogen or Acrux or Factor Theraputics or Oncosil shareholders for the control arm?

There are plenty of biotech's with agitated shareholders to choose from........

Measuring the calming effect would be the other challenge I guess.